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A B S T R A C T
Background: Fatty acids and their derivatives are one of the most crucial inﬂammation mediators. The
aim of our study was to evaluate the impact of polyunsaturated fatty acids as eicosanoids precursors on
the A549 cell line.
Methods: Cells were incubated with 40 mM of arachidonic, eicosapentaenoic or docosahexaenoic acid
for 24 h, then activated with LPS. Fatty acids content in the cell membranes were determined using gas
chromatography. COX-2, cPGES and FP-receptor quantities were determined by Western blot. 8-
Isoprostane F2a concentrations were determined by EIA. Maresin and protectin D1 contents were
analyzed by UHPLC/MS-TOF method.
Results: Signiﬁcant differences in membrane fatty acids and levels of 8-isoPGF2a in the activated cells
were detected. Elevated expression of COX-2 and FP-receptor was observed in cells treated with AA and
activated with LPS. Moreover, compared to AA and AA + LPS groups, cells incubated with EPA, DHA,
EPA + LPS and DHA + LPS showed decreased expression of COX-2, cPGES and FP-receptor. In cells
incubated with EPA or DHA and activated with LPS maresin and protectin D1 were detected.
Conclusions: The results of the study have revealed the pro-inﬂammatory properties of AA, while the EPA
and DHA had the opposite, resolving effect. Interestingly, FP-receptor inhibition by EPA and DHA
demonstrated the unique role of the FP-receptor as a potential target for antagonists, in the diseases of
inﬂammatory character. This study provides new information about n-3 fatty acids and their pro-
resolving mediators, which can be used in the process of developing new anti-inﬂammatory drugs.
 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp.
z o.o. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate /p h arepIntroduction
Eicosanoids are one of the most crucial inﬂammation media-
tors. Their pro-inﬂammatory properties were well known,
however, current studies focus on the anti-inﬂammatory effect
of fatty acids derivatives.Abbreviations: AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahex-
aenoic acid; LPS, lipopolysaccharide; 8-isoPGF2a, 8-iso prostaglandin F2a; PTGS2,
prostaglandin synthase 2; COX-2, cyclooxygenase-2; cPGES, cytosolic prostaglan-
din E synthase 3; FP-receptor, prostaglandin F2a receptor; 7(R)-MaR1, 7(R)-
Maresin; protectin DX, 10(S),17(S)-DiHDoHE, protectin D1.
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1734-1140/ 2015 Institute of Pharmacology, Polish Academy of Sciences. Published bThe basic physiological mechanisms that may regulate the
inﬂammatory process, which is genetically determined, include the
endogenous eicosanoids system and apoptosis. Inﬂammation is a
defensive reaction of living tissues to injury. Acute inﬂammation
may go into a chronic form, with adverse health consequences in the
form of difﬁcult-to-treat chronic diseases. Studies of the mediators of
inﬂammation arising from fatty acids led to the identiﬁcation of the
anti-inﬂammatory potential of polyunsaturated fatty acids (PUFAs).
These lipid mediators exert their anti-inﬂammatory effects in a
receptor-dependent manner. The most important effects contribut-
ing to the inﬂammatory response are: inhibition of neutrophil
mobilization and transmigration, suppression of pro-inﬂammatory
cytokine secretion by various cells present in the region ofy Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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monocytes and macrophages. The molecular mechanism to
resolve the inﬂammatory response by lipid mediators is not fully
elucidated [1–4].
Lipids are essential molecules for the structure of cells and
organelles. Cellular membranes require speciﬁc structural motifs
for optimum functionality both under physiological conditions and
to withstand cellular stresses. Thus, complex metabolic pathways
are needed to properly synthesize and degrade membranes,
depending on the needs of the cell. However, in multicellular
organisms, a large fraction of the organism’s effort must be spent
on intercellular communication, so that different cells and tissues
may function in synchrony [5–8].
Understanding the immune–metabolic interface is daunting.
One contemporary issue is characterizing the sources and
mediators of chronic low-level metabolic inﬂammation, which
were ﬁrst characterized in adipose tissue, but are now known to be
present in many different tissues including the liver, muscle,
pancreas and hypothalamus. A greater understanding of the
critical nodes of immune-metabolism may provide opportunities
to break the tight connection of defects in metabolism and
immunity that propagate disease [9–16].
The dense clustering of different cell types during inﬂammation
presents a unique situation for how lipids are handled. In contrast
to the synthesis of protein mediators (cytokines), lipid mediators
can be produced along enzymatic pathways that involve multiple
cells, in a process known as trans-cellular biosynthesis. In essence,
the inﬂamed tissue becomes a specialized organ for lipid
metabolism, producing the types and amounts of lipid mediators
needed to promote or resolve inﬂammation [1–4].
The aim of this study was to evaluate the pro- or anti-
inﬂammatory impact of n-3 and n-6 PUFAs as eicosanoid
precursors on COX-2, cPGES and FP-receptor expression and on
the 8-isoPGF2a, maresin and protectin D1 formation in the human
lung epithelial cancer A549 cells activated with LPS.
Materials and methods
Reagents
8-iPGF2a, 8iPGF2a-d4, 10(S),17(S)-DiHDoHE, 7(R)-Maresin
were obtained from Cayman Chemical Company (Michigan,
USA). LC–MS grade methanol, BHT, AA, EPA and DHA, KOH, were
purchased from Sigma–Aldrich (St. Louis, USA). Formic acid was
supplied by Merck (Darmstadt, Germany).
Cell cultures
Human Lung Carcinoma Epithelial Cells (A549, ATCC CCL-185)
were cultured in F 12K Medium (ATCC) with 10% Fetal Bovine
Serum (ATCC, LGC Standards, Poland) and the following anti-
biotics: penicillin (100 IU/ml) and streptomycin (100 mg/ml)
(ATCC). Cells were maintained at 37 8C in a humidiﬁed atmosphere
which contained 5% CO2 and were seeded into a 6-well plate
(Sarsted, Germany) at a density of 5  105 cells/well in 2 ml of
medium. During every step of the procedure, cell morphology was
investigated by an inverted light microscope (Olympus, Japan). Cell
viability during culturing was assessed using the Trypan Blue
Exclusion Test.
A549 cells were incubated with 4 ml of arachidonic, eicosa-
pentaenoic or docosahexaenoic acid (AA, EPA and DHA dissolved in
ethanol to a ﬁnal concentration of 10 mM/ml) for 24 h combined
with 1 ml of LPS dissolved in PBS to a ﬁnal concentration of 10 ng/
ml for 24 h. Control cultures received the same concentration of
ethanol (the ﬁnal content did not exceed 0.12%, v/v) and PBS as
experimental cells.ApoTox-Glo Triplex Assay
The ApoTox-Glo Triplex Assay was performed to assess cell
viability, the potential cytotoxicity of AA, EPA, DHA and LPS, as well
as cell apoptosis, as per manufacturer instructions (Promega, MI,
USA). Absorbance, ﬂuorescence and luminescence were measured
using the FLUOstar Omega plate reader (BMG LABTECH, Germany).
Fatty acid analysis
Cell membranes were prepared by hypotonic hemolysis at 4 8C
in 10 mM Tris with pH = 7.4. Membranes were then isolated by
centrifugation (10,000  g, 15 min) according to the method
proposed by Graham [17].
Total lipid extraction from the cell membranes was carried out
using a solution of chloroform/methanol (2:1) [18]. The synthesis
of fatty acid methyl esters from the membranes was carried out
with 14% BF3 in methanol [19]. The FA methyl esters were analyzed
using gas chromatography (Agilent 6890N) with a DB-23 (60 m,
0.25 mm) column as described earlier [20]. Fatty acid methyl esters
were identiﬁed according to standards (Sigma–Aldrich). The data
were analyzed using ChemStation. Results were expressed in
relative percentage of the sum of saturated (SAT), unsaturated
(UNSAT), monounsaturated (MUFA), n-3 and n-6 FA.
8-Isoprostane Express EIA Kit
In the cell samples after SPE extraction 8-isoPGF2a concentra-
tions were detected with 8 Isoprostane Express EIA Kit, according
to the manufacturer instructions (Cayman Chemical). Absorbance
was measured at the FLUOstar Omega plate reader (BMG LABTECH,
Germany).
UHPLC/MS-TOF method
Identiﬁcation and determination of 7(R)-Maresin 1, 10(S),17(S)-
DiHDoHE was performed using an UltiMate 3000 RS liquid
chromatography system (Dionex, USA) coupled to a mass spec-
trometer with a time of ﬂight mass analyzer (MicroTOF-Q II, Bruker,
Germany). Separation of the studied eicosanoids was carried out on a
Synergi 4m Hydro-RP 80A column (150 mm  2.0 mm I.D., Phe-
nomenex, USA) at 40 8C. The mobile phase was prepared by
mixing methanol and 0.01% formic acid according to a gradient
program: MeOH: 0 min – 20%; 18 min – 100%, 20–22 min – 20%, ﬂow
0.2 ml/min. The [MH]masses with the deﬁned retention time (Rt)
were: for the 17(S)-DiHDoHE m/z = 359.222  0.005 (Rt = 19.83),
for 7(R)-Maresin 1 m/z = 359.222  0.005 (Rt = 20.03 min). The
details and validation parameters of the method were described
earlier [21].
Western blot for COX-2, cPGES and FP-receptor quantities
Cell lysates were prepared using Mammalian Protein Extraction
Reagent (M-PER, Thermo Scientiﬁc, Rockford, IL, USA) with
protease inhibitor cocktail set III (Calbiochem, Merck, Germany).
Protein concentrations were determined using the Bradford
reaction. Aliquots (20 mg of protein) were solubilized in a Laemmli
buffer with 2% 2-mercaptoethanol (Bio-Rad, Hercules, CA, USA)
and subjected to 10% SDS–polyacrylamide gel electrophoresis.
Protein extracts were transferred to PVDF membranes using a
trans-blot (Bio-Rad). Following transfer, membranes were blocked
in the presence of casein in TBS-1% Tween buffer (Bio-Rad) and
subsequently incubated either with COX-2, cPEGS primary
antibodies diluted 1:1000 in Signal+ for Western blot (GeneTex,
Irvine, CA, USA), FP-receptor primary antibody (Cayman Chemical)
diluted 1:500 in Signal+ (GeneTex) and b-actin diluted 1:1000 in
Table 1
Fatty acid proﬁles of the membranes of A549 cells. Data are expressed as [%]. Means  SD, n = 6.
Control LPS AA AA + LPS EPA EPA + LPS DHA DHA + LPS p
SAT 40.8  3.2 35.1  2.5* 34.5  2.4* 33.3  3.1* 40.0  3.5 45.4  1.2** 46.1  2.5** 46.4  3.2** 0.05
UNSAT 59.2  2.9 64.9  3.5* 65.5  3.8* 66.7  2.7* 60.0  2.2* 54.6  2.0 53.9  3.0 53.6  4.0 0.05
MUFA 25.3  1.7 23.7  1.2 23.8  1.5 17.2  1.1* 21.2  0.8 31.7  2.6** 22.7  2.4 30.7  3.6** 0.05
n-3 4.4  0.5 2.7  0.2* 2.9  0.4* 4.0  0.6 25.1  1.3** 9.8  0.8*** 17.8  1.1** 10.6  2.2*** 0.04
n-6 29.5  1.4 38.5  2.8* 38.8  2.5* 45.5  3.1* 13.7  1.2** 13.1  2.4* 13.4  1.4** 12.3  2.6** 0.03
n-3/n-6 0.1  0.0 0.1  0.0 0.1  0.0 0.1  0.0 1.8  0.4 0.7  0.1** 1.3  0.1* 0.6  0.1** 0.01
SAT, sum of saturated FAs; UNSAT, sum of unsaturated FAs; MUFA, sum of mono-unsaturated FAs; n-3, sum of n-3 FAs; n-6, sum of n-6 FAs; n-3/n-6, n-3/n-6 FAs ratio.
*, **, *** – asterisks denoted statistical signiﬁcant differences between groups.
Fig. 1. 8-iso prostaglandin F2a concentration [ng/ml] in A549 cells incubated with
AA or EPA and activated with LPS. Means  SD, n = 6.
Fig. 2. Chromatogram of maresin and protectin D1.
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with Easy Blot anti-rabbit IgG (HRP) as secondary antibodies
(GeneTex). The membranes were washed, and proteins were
detected using a Clarity Western ECL Luminol Substrate (Bio-Rad)
Western blot detection kit. The integrated optical density of the
bands was quantiﬁed using Chemi Doc Camera with Image Lab
software (Bio-Rad).
Statistical analysis
All experiments were performed six times. All data are
presented as means  SD. Differences between groups were deter-
mined using the one-way ANOVA, or the Kruskal–Wallis test if
normality was not observed. Calculations were performed using
Statistica 10 (StatSoft, Poland) software, and statistical signiﬁcance
was deﬁned as p  0.05.
Results
Cells viability
No cytotoxic effects were observed in the A549 cells treated
with AA, EPA or DHA for 24 h and activated with LPS for 24 h.
Caspase-3/7 activity increased in the cells treated with LPS and
AA + LPS. Cells viability decreased from 99% to 95% after incubation
with LPS for 24 h. There were no apoptotic cells after treatment
with these compounds.
Fatty acids content
In the A549 cells we observed differences in the content of
membrane fatty acids between all experimental groups. Control
cells had 40.8% SAT and 59.2% UNSAT FA. After activation with LPS
increases in UNSAT FA were observed (p  0.05). Cells treated with
EPA and LPS and with DHA and LPS had decreased UNSAT indices
compared to controls. In the group supplemented with AA and
activated with LPS the MUFA index was the lowest (17.2%)
compared to other groups while in the cells incubated with EPA
and LPS the MUFA index was the highest (31.7%) (p  0.05). The
highest concentration of n-6 FA was observed in the AA + LPS
samples (45.5%); the lowest amount of n-6 FAs were observed in
the A549 cells incubated with EPA, DHA and EPA + LPS. We
observed a decreased amount of n-3 FAs in all groups treated with
LPS (Table 1).
8-isoPGF2a, maresin and protectin D1 content
The highest amount of 8-iso prostaglandin F2a was detected in
A549 cells activated with LPS (1.45 ng/ml) and in the cells
supplemented with AA and activated with LPS (1.62 ng/ml)
(p  0.05). For the cells incubated with AA the content of
8-isoPGF2a was lower (0.76 ng/ml), but differ statistically
between others groups (p  0.05). In the cells supplemented withEPA or DHA and activated with LPS we observed the same level of
8-isoPGF2a (0.22 ng/ml) which did not differ statistically between
control, EPA or DHA cells (Fig. 1).
After UHPLC/MS-TOF analysis we detected maresin and
protectin D1 only in the cells supplemented with EPA or DHA
and activated with LPS. The content of maresin was 1.58 ng/ml, and
PDX concentration was 1.56 ng/ml in the EPA + LPS group. In the
DHA + LPS group we observed higher content of maresin (1.70 ng/
ml) and protectin D1 (1.67 ng/ml) (Figs. 2 and 3).
COX-2, cPGES and FP-receptor expression
The highest amount of COX-2 compared to control was
observed in A549 cells activated with LPS and incubated with
AA + LPS. Also higher expression of this protein was observed in the
Fig. 3. Maresin and protectin D1 content [ng/ml] in A549 cells supplemented with
EPA or DHA and activated with LPS, n = 6.
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level in the samples incubated with EPA, DHA, EPA + LPS and
DHA + LPS compared to the other groups (Fig. 4).
The highest amount of prostaglandin E synthase was observed
in the control, AA + LPS and DHA cells. In samples incubated with
LPS, AA, EPA, DHA + LPS the level of protein was lower.
Supplementation with EPA + LPS caused decreased expression of
cPGES compared to the other groups (Fig. 4).
The highest expression of FP-receptor was observed in cells
activated with LPS and in the cells AA + LPS. Also high amount
of this protein was observed in cells incubated with AA
compared to control, EPA and DHA samples. In the cells from
EPA + LPS and DHA + LPS groups expression of FP-receptor was
higher (Fig. 4).Fig. 4. Relative expression of (a) COX-2, (b) cPGES and (c) FP-receptorDiscussion
In the present study human lung epithelial carcinoma cells
(A549) were incubated with arachidonic, eicosapentaenoic or
docosahexaenoic acids for 24 h. Then, cells were activated with
LPS for 24 h. A549 cells could synthesize lecithin with a high
percentage of desaturated FAs using the cytidine diphosphocholine
pathway, so they are an excellent choice to study lipid interactions,
metabolism, and signaling [22,23].
Our study is the ﬁrst of its kind in that it evaluated the FA proﬁle
of A549 cell membranes activated with LPS, 8-isoPGF2a levels,
maresin and protectin DX content and COX-2, cPGES and FP-
receptor activity together.
Our major ﬁndings are as follows: (1) supplementation of A549
cells with AA, EPA, DHA or LPS had no effect on viability or
apoptosis; (2) there were differences in the content of membrane
fatty acids upon activation with LPS; (3) cells incubated with EPA
and DHA and activated with LPS had a decrease in cyclooxygenase,
prostaglandin E synthase and FP-receptor expression, compared to
AA + LPS cells; (4) the level of 8-isoPGF2a after incubation with
EPA + LPS and DHA + LPS was signiﬁcantly lower compared to cells
treated with AA and LPS, moreover in both groups maresin and
protectin D1 were detected, which may be due to the antioxidant
and pro-resolving properties of n-3 fatty acids. n-3 PUFAs exert
anti-inﬂammatory actions by inhibiting pro-inﬂammatory signal
transduction pathways whereas n-6 PUFAs facilitate inﬂammation
by serving as a precursor of pro-inﬂammatory eicosanoids
[7,9,12]. n-3 and n-6 FAs are ligands/modulators for the nuclear
receptors NF-kB, PPARs and SREBP-1c, which control various
genes of inﬂammatory signaling and lipid metabolism. n-3 FAs
down-regulate inﬂammatory genes and lipid synthesis, and
stimulate FA degradation. In addition, the n-3/n-6 PUFA content in A549 cells incubated with AA or EPA and activated with LPS.
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domains strongly inﬂuence membrane function and numerous
cellular processes such as cell death and survival [1,24–27].
Mickleborough et al. determined which of the active consti-
tuents of ﬁsh oil, EPA or DHA, is most effective in suppressing pro-
inﬂammatory mediator generation and cytokine expression from
LPS-stimulated human asthmatic alveolar macrophages. The
authors showed for the ﬁrst time that EPA is a more potent
inhibitor of inﬂammatory responses in human asthmatic AMphi
cells than DHA [28]. Saedisomeolia et al. determined that EPA and
DHA reduced the release of inﬂammatory mediators from airway
epithelial cells infected with rhinovirus (RV). Authors observed
that cellular DHA content negatively correlated with IL-6 and IP-10
release. It was concluded that DHA has a potential role in
suppressing RV-induced airway inﬂammation [29].
The results of our study have revealed the pro-inﬂammatory
properties of AA, while the EPA and DHA supplementation had the
opposite, anti-inﬂammatory, resolving effect on the A549 cells. Our
data are similar to results observed by Saw et al. [30]. Authors
examined whether curcumin with DHA or EPA would have
synergistic anti-inﬂammatory effects in RAW 264.7 cells and
showed the synergistic anti-inﬂammatory as well as anti-oxidative
stress effects of curcumin and PUFAs [30]. Wang et al. investigated
the role of Nrf2 in suppressing LPS-mediated inﬂammation in ex
vivo macrophages by the DHA and EPA. Researchers observed that
DHA and EPA inhibited LPS-induced COX-2, iNOS, IL-1b, IL-6, or
TNF-a, but increased hemeoxygenase (HO-1) expression [5]. Our
studies on cells activation with LPS and supplemented with n-3 FAs
conﬁrmed this observation.
In our study, cells incubated with EPA, EPA with LPS, DHA
and DHA with LPS had a decrease in cyclooxygenase and FP-
receptor expression compared to the AA and AA + LPS groups,
which demonstrates the anti-inﬂammatory properties of the
EPA and DHA fatty acids. Interestingly, FP-receptor inhibition by
EPA and DHA or their derivatives demonstrated the unique role
of the FP-receptor as a potential target for antagonist in the
diseases of inﬂammatory character. Because COX-2 is a key
enzyme in the inﬂammatory response, increasing the expression of
this protein by some compounds may be regarded as a pro-
inﬂammatory characteristic. In lung epithelial cells, the pro-
inﬂammatory actions of AA were very pronounced in cells
incubated with AA, both with and without LPS activation.
The samples of A549 cells incubated with EPA showed decreased
COX-2 activity.
The formation of PGE2 from PGH2, by COX-1 or COX-2 is
catalyzed by isomerases, three different PGE synthases: cPGES, and
two membrane-bound PGE synthases: mPGES-1 and mPGES-2. In
immediate PG biosynthesis, which occurs within several minutes
after stimulation with agonists that increase cytoplasmic Ca2+
levels, cytosolic phospholipase A2 (cPLA2) is a prerequisite for
supplying AA to the COX-1. Delayed PG biosynthesis, which
proceeds gradually over a long term period after a pro-
inﬂammatory stimulus, is accompanied by de novo induction of
COX-2, which is an absolute requirement irrespective of the
coexistence of COX-1. When cells are ﬁrst treated with pro-
inﬂammatory stimuli and subsequently exposed to Ca2+ mobili-
zers, the inducible COX-2 can also promote an immediate response
[25,26,31,32].
In our study we observed that supplementation of cells with
EPA and LPS caused decreased expression of cPGES, compared to
the other groups. These results conﬁrmed by the results received
for other authors, suggested pro-resolving action of eicosapenta-
enoic acid.
Wortman et al. showed that EPA-mediated inhibition of AA
metabolism did not signiﬁcantly alter fatty acid synthase (FAS)
activity, while both AA and EPA signiﬁcantly decreased FAS mRNAexpression. COX-2 inhibition signiﬁcantly decreased PGE2 produc-
tion resulting in a decrease in FAS activity and expression
suggesting an additional mechanism that is independent of
COX-2 [33]. In the study by Li et al., DHA pretreatment for 24 h
attenuated macrophage activation primarily via inhibition of COX-
2 induction and activity induced by LPS, with no effects on COX-1.
These effects were different from EPA’s actions, which lead to
inhibition of PG biosynthesis by dampening COX-1. Authors
observed that DHA is a more potent inhibitor of COX-2 than COX-1
in terms of PG biosynthesis. Moreover, they showed that DHA also
suppresses mPGES-1 expression with prolonged stimulation [7].
EPA competes with AA for release from membrane phospho-
lipids and for metabolism to eicosanoids by COX and LOX. Some
studies demonstrated that systemic EPA supplementation can
signiﬁcantly reduce the levels of the key pro-inﬂammatory
mediators PGE2 and 12-HETE relative to their EPA-derived
counterparts PGE3 and 12-HEPE, which may have important
consequences for regulation of responses to inﬂammatory stimuli
[4,8,34].
Not only can EPA replace arachidonic acid in phospholipid
bilayers but is also a competitive inhibitor of cyclooxygenase.
Some studies suggest that the beneﬁcial effects of n-3 FAs may be
mediated, in part, by the anti-inﬂammatory effects of oxidized EPA
[11,27,35].
Endogenous mediators of inﬂammation and mechanisms
involved in regulating this process, as well as, its resolution are
of wide interest, and thus their tissue signature proﬁles may be
useful in characterizing health and disease states, as well as in
monitoring the design and impact of new treatments [1,2]. New
class of mediator now comprises several new families enzymati-
cally derived from n-3 PUFAs, including E- and D-series resolvins,
(neuro)protectins, and maresins [3,4,9].
The antioxidant properties n-3 FAs and its pro-resolving
properties were observed in our study. In the A549 cells
supplemented with EPA or DHA and activated with LPS, maresin
and protectin D1 were detected.
Isoprostanes are good markers of lipid peroxidation; they are
formed by a free-radical attack on AA localized in cellular
membranes. Currently, 8-iso prostaglandin F2a is the best
characterized and the most often studied isoprostane. Separate
evidence has suggested that cyclooxygenase activity may also
contribute to isoprostane production in selected tissues [4,36].
After analysis we observed that 8-isoPGF2a concentrations were
the higher in A549 cells incubated with LPS and in AA + LPS. The level
of 8-isoPGF2a after incubation with EPA or DHA and LPS was
signiﬁcantly lower. These results are comparable to those obtained
by Gdula-Argasin´ska et al. [21]. Researchers used human HepG2
cells and estimated the effect of supplementation with EPA and
treatment of benzo(a)pyrene. Analysis showed the presence of lipid
derivatives of EPA – PGF3a, 8-iPGF3a, and AA derivatives. Authors
demonstrated that EPA has an anti-oxidative stress effect under
benzo(a)pyrene exposition. Their ﬁndings strongly suggest that
EPA plays a role in the enhancement of anti-oxidant defense [21].
Changing the FA composition of the membrane cells also affects
their properties, function, and cell signaling [37,38]. These effects
appear to mediated at the membrane level suggesting the
important roles that FAs play in membrane order, lipid raft
structure and function, and membrane trafﬁcking.
In the presented study there were signiﬁcant changes in the
FA proﬁle in all groups of cells, those LPS-activated and those
supplemented with AA or EPA in relation to the control group. It
was found that the LPS-activated cells displayed signiﬁcantly
increased n-6 FAs, with the exception of LPS-activated A549 cells
and supplemented with EPA or DHA. Differences in the membrane
FA proﬁles of cells may result from the use of FA for biosynthesis
of eicosanoids and from differential expression of genes involved in
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tory conditions. Therefore enzymes that regulate FA metabolism
are attractive candidates to better understand the relationship
between FA and inﬂammation [25,33,37,39]. Stearoyl-CoA desa-
turase 1 (SCD1) is rate limiting for the conversion of saturated FA to
monounsaturated FA. Evidence suggests that SCD1 activity may be
positively associated with inﬂammation. Moreover, genetic varia-
tion in SCD1 may alter enzyme activity; however, it is unknown
whether this affects inﬂammatory status [37].
Fatty acids and lipid metabolites that are ligands for PPARs and
NF-kB transcription factors are likely to be used as nutraceuticals
in the regulation of the immune response.
In conclusion, the results of the study have revealed the pro-
inﬂammatory properties of AA, while the EPA and DHA had the
opposite, resolving effect. Interestingly, FP-receptor inhibition by
EPA and DHA demonstrated the unique role of the FP-receptor as a
potential target for antagonists, in the diseases of inﬂammatory
character. This study provides new information about n-3 FAs and
their pro-resolving mediators, which can be used in the process of
developing new anti-inﬂammatory drugs.
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